Drug intelligence / Profile preview

chlorphenesin carbamate + hydroxychloroquine

Development stage: Unknown
Lead developer: Oncocross
Modality: Small Molecules
Administration: Oral

Overview

OC212e is an orally administered combination therapy consisting of chlorphenesin carbamate (OC201) and hydroxychloroquine (OC202e), discovered using Oncocross's proprietary AI platform, RAPTOR AI. It is developed for the treatment of advanced pancreatic cancer and the inhibition of cancer metastasis. Chlorphenesin carbamate acts as an inhibitor of AKT-mediated epithelial-mesenchymal transition (EMT) and PKCε signaling, while hydroxychloroquine acts as an autophagy inhibitor by preventing lysosomal acidification. Together, they synergistically suppress EMT, cancer cell invasion, and metastasis. In a multi-center Phase 2 clinical trial in South Korea, OC212e in combination with mFOLFIRINOX demonstrated a manageable safety profile and promising efficacy in patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma, achieving a median overall survival of 14.8 months.

Other names: OC201 + OC202eOC201/OC202echlorphenesin carbamate and hydroxychloroquine

Targets

PRKCE (Protein Kinase C epsilon)AKT (RAC-alpha serine/threonine-protein kinase)

Beyond the preview

Go deeper on chlorphenesin carbamate + hydroxychloroquine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chlorphenesin carbamate + hydroxychloroquine.

Explore the full profile